CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2012-05-09): Metformin may prevent liver cancer in type 2 diabetes

Clinical

Metformin may prevent liver cancer in type 2 diabetes

Last Updated: 2012-05-09 15:30:12 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Metformin appeared to lower the risk of developing liver cancer in patients with type 2 diabetes, in a meta-analysis reported online April 20th.

But the authors cautioned, in the Journal of Clinical Endocrinology and Metabolism, that more research, "including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is needed."

Dr. Zhi-Jiang Zhang, with the School of Public Health at Shanghai Jiao Tong University, China, and colleagues say the risk of liver cancer is approximately doubled in patients with diabetes. Earlier studies have indicated that metformin may have a preventive effect against liver cancer as well as colorectal cancer and several other types of cancer.

To investigate further, the team searched the literature for case-control studies or cohort studies that examined the effect of metformin on hepatocellular carcinoma or primary liver cancer in patients with type 2 diabetes.

Data were abstracted from five relevant studies involving a total of 105,495 type 2 diabetics. Compared to no metformin treatment, metformin use was associated with an odds ratio of 0.38 for liver cancer (p<0.001), the authors report

"A latency time period was considered in four of the five included studies, although the possibility of reverse causation is not completely ruled out," the authors note.

They comment that metformin would be attractive for cancer chemoprevention if it is ultimately shown to reduce the risk of liver cancer, since it is well tolerated and inexpensive. "In this regard, it is instructive that the less developed countries have been disproportionately affected by liver cancer, accounting for nearly 85% of total new liver cancer cases worldwide. Thus, the affordability of metformin is important for accessibility to the general population."

SOURCE: http://bit.ly/J1eWlW

J Clin Endocrino Metab 2012.

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.